ABC | Volume 112, Nº4, Abril 2019

Artigo de Revisão Ferrari et al Inibidores da PCSK9 na prática clínica Arq Bras Cardiol. 2019; 112(4):453-460 Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons 38. Urban D, Poss J, Bohm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol. 2013;62(16):1401-8. 39. Cheng JM, Oemrawsingh RM , Garcia-GarciaHM, Boersma E, vanGeuns RJ, Serruys PW , et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016May;248:117-22. 40. Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever OS, et al. Inflammatory and cholesterol risk in the FOURIER trial. Circulation. 2018;138(2):131-40. 41. Liberale L, Montecucco F , Camici GG, Dallegri F , Vecchie A, Carbone F, et al. Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce cardiovascular inflammation and outcomes. Curr Med Chem. 2017;24(14):1403-16. 42. Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, et al. PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep. 2018;8(1):2267. 43. Bernelot Moens SJ , Neele AE, Kroon J, van der Valk FM, Van den Bossche J, Hoeksema MA, et al. PCSK9 monoclonal antibodies reverse the pro- inflammatory profile of monocytes in familial hypercholesterolaemia. Eur Heart J. 2017;38(20):1584-93. 44. Mefford MT, Rosenson RS, Cushman M, Farkouh ME, McClure LA, Wadley VG, et al. PCSK9 variants, low-density lipoprotein cholesterol, and neurocognitive impairment: reasons for geographic and racial differences in stroke study (REGARDS). Circulation. 2018;137(12):1260-69. 45. Harvey PD, Sabbagh MN, Harrison JE, Ginsberg HN, Chapman MJ, ManvelianG, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J. 2018;39(5):374-81. 46. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al. Do statins impair cognition? a systematic review and meta-analysis of randomized controlled trials. J Gen Intern Med. 2015;30(3):348-58. 47. Khan AR, Bavishi C, Riaz H, Farid TA, Khan S, Atlas M, et al. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes. 2017;10(1):pii:e003153. 48. Giugliano RP , Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633-43. 49. Giugliano RP , Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondaryanalysisoftheFOURIERtrial. Lancet.2 017;390(10106):1962-71. 50. Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531-40. 51. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870-82. 52. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2541-8. 53. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. JAMA. 2016;315(15):1580-90. 54. Hall SS. Genetics: a gene of rare effect: a mutation that gives people rock- bottom cholesterol levels has led geneticists to what could be the next blockbuster heart drug. Nature [periódicos na Internet]. 2013 [acesso 16 apr 2018];496(7444). Disponível em: https://www.nature.com/news/genetics- a-gene-of-rare-effect-1.12773. 55. HacquebardM, Carpentier YA. Vitamin E: absorption, plasma transport and cell uptake. Curr Opin Clin Nutr Metab Care. 2005;8(2):133-8. 56. Qamar A, Bhatt DL. Effect of low cholesterol on steroid hormones and vitamin E levels: just a theory or real concern? Circ Res. 2015;117(8):662-4. 57. Blom DJ, Djedjos CS, Monsalvo ML, Bridges I, Wasserman SM, Scott R, et al. Effects of evolocumab on vitamin E and steroid hormone levels: results from the 52-Week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ Res. 2015;117(8):731-41. 58. Stam-Slob MC, van der Graaf Y, de Boer A, Greving JP, Visseren FLJ. Cost- effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol. 2018 Feb 15;253:148-54. 59. McDonagh M, Peterson K, Holzhammer B , Fazio S. A systematic review of PCSK9 inhibitors alirocumab and evolocumab. J Manag Care Spec Pharm. 2016;22(6):641-653q. 60. Soarez PCD, Novaes HMD. Cost-effectiveness thresholds and the Brazilian Unified National Health System. Cad. Saude Publica. 2017;33(4):e00040717. 61. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA. 2017;318(8):748-50. 62. FonarowGC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, et al. Cost-effectiveness of Evolocumab Therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMACardiol. 2017;2(10):1069-78. 63. Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol. 2017;2(12):1369-74. 460